Eimicro: in silico organism design platform for enhanced protein production
eiMICRO is an innovative in silico organism design platform that utilizes ultra-high-throughput screening to optimize microbial strains for high-titer protein production. It accelerates strain development, increasing yield and cost efficiency in precision fermentation.
Overview
eiMICRO represents a significant advancement in the design and optimization of microbial strains for protein production. Developed by Triplebar Bio Inc, this platform leverages ultra-high-throughput screening to generate extensive genomic datasets, linking genotype to high titer outputs. By dramatically increasing the throughput of microbial assessments, eiMICRO can evaluate tens of millions of strains in a single day. This capability allows for the rapid identification and sequencing of top-performing strains, which are then used to fine-tune genome language models. The ultimate goal of eiMICRO is to enable product developers and manufacturing experts to swiftly design high-titer strains, thus enhancing the efficiency and yield of precision fermentation-derived ingredients such as sweeteners, colors, preservatives, and antioxidants.
Technical specifications
- Ultra-high-throughput screening: Evaluates tens of millions of microbial variants daily, identifying top performers for sequencing.
- Genome language models: Utilizes large phenotypically labeled genomic datasets to predict and improve strain function.
- Directed evolution workflow: Involves multiple rounds of strain sorting and validation using quantitative assays, microtiter plates, and fed-batch bioreactors.
- Focus on protein production: Optimizes strains for producing proteins used in various applications including sweeteners, colors, and preservatives.
Technology readiness level
The eiMICRO platform is currently at Technology Readiness Level 6. It has undergone testing in relevant environments and is ready for further validation and optimization with partners interested in increasing strain productivity and yield. Triplebar Bio Inc is seeking collaborations with product developers and manufacturing experts to enhance the development speed and market success of precision fermentation products.
About Triplebar Bio Inc
Triplebar Bio Inc. is a biotechnology company that integrates hardware, software, and biology to accelerate the discovery and production of therapeutics and sustainable food products. The company’s core technology is a proprietary microfluidics platform that miniaturizes biological testing into picoliter-volume microreactors. This system allows for the screening of tens to hundreds of millions of individual cells daily to analyze their phenotype and genotype. By combining this high-throughput data generation with generative AI genome language models, Triplebar enables Genomic Design Automation (GDA), which significantly reduces the time and cost required for strain and cell line engineering compared to traditional methods.
This technology provides vital solutions for the healthcare and food industries by streamlining the development of high-performance biologics and alternative proteins. The platform, which includes specialized tools like eiCHO for biologics production and eiMICRO for cell line engineering, helps partners navigate the complexities of biological systems more efficiently. By identifying optimal cellular behaviors at hyperspeed, Triplebar enables companies to bypass lengthy, manual lab processes, supporting the creation of sustainable and cost-effective solutions for global supply and health challenges. The company, headquartered in Emeryville, California, has attracted significant investment to scale its efforts in re-engineering production systems across the life sciences.
delivered to your inbox.